News

Order free copies online of this new mini-guide…

Reports from three conferences. Guidelines. Buying generic PrEP and HCV meds; TTIP; first UK PrEP clinic…

This article is also included in the September/October issue of HTB. https://i-base.info/htb/28949 Simon Collins, HIV i-Base On 30 September 2015, the World Health Organization (WHO) issued a new 78-page guideline document on two important changes to current treatment recommendations. [1, 2] The …

Biggest changes for 10 years: earlier ART, treatment as prevention, efavirenz dropped… and new challenges for the NHS… New online guide and A5 booklet.

IAS 2015 – a time of global change for HIV care: over a dozen reports on why this conference news is so exciting…

START results in full, WHO recommends ART for all, HIV cure research, webcasts access, treatment as prevention in HPTN 052, HIV remission in a teenager, dispersible dolutegravir for kids, new ARVs and more…

Activist review of latest research into HIV, HCV and TB: drugs for adults and children, dose optimisation, diagnostics, prevention, cure and vaccines…

Remembering Professor Martin Fisher, breaking news on the START study, reports from BHIVA, CROI and HIV & Women conferences and much more…

What is the START study? The START study is a large international HIV study. It looks at the risks and benefit of early HIV treatment. “Early” is defined as having a CD4 count above 500. Results are compared to a …

At least 18 months earlier than expected, these results will change treatment guidelines globally…

News, comment and reviews of more than 50 studies in 16 articles from CROI 2015 and 4 from the International Drug Resistance Workshop…

All about PrEP – 6 studies plus ART prevention, 3-drug ART for PMTCT, HIV drug resistance, new drugs: TAF and maturation inhibitors, why TEMPRANO does not support early ART, weekends-off ART for some young people…

Reports from hepatitis and TB meetings, dolutegravir in England, new London guidelines, India rejects patent for Gilead’s sofosbuvir, plus more…

NHS England approves dolutegravir and Triumeq and London guidelines updated for when these drugs can be prescribed…

Stock-outs in the UK, conference reports from Glasgow, BHIVA and South Africa, plus the PROUD and IPERGAY studies and new UK data show urgency of PrEP access…

This is a pre-press article for the November/December edition of HTB. Simon Collins, HIV i-Base Serious vision loss linked to recreational use of poppers has been reported as a case study in this weeks issue of the Lancet. The vision …

Simon Collins, HIV i-Base On 29 October 2014, French and Canadian researchers announced early efficacy of a PrEP study to protect gay men from catching HIV. This has led to a change in the study design. [1] The IPERGAY study is …

NOTE: Please see this updated information about the PROUD results and access to PROUD in the UK. https://i-base.info/uk-proud-study-to-provide-prep-earlier-than-expected The following Q&A was produced by i-Base about PrEP in the UK including recent changes to the PROUD study. Participants in the …

Important news for PrEP in the UK

Please click title link for the download page.